The impact of preoperative 5-alpha reductase inhibitors on functional outcomes and health-related quality of life following radical prostatectomy - A propensity score matched longitudinal study
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Preoperative 5-alpha reductase inhibitor (5-ARI) use before prostate cancer surgery is linked to worse long-term urinary continence recovery. This impacts patient-reported outcomes following radical prostatectomy.
Area Of Science
- Urology
- Oncology
- Patient-Reported Outcomes
Background
- 5-alpha reductase inhibitors (5-ARI) impact on prostate cancer (PC) mortality is known.
- The effect of preoperative 5-ARI on patient-reported outcomes (PROs) after radical prostatectomy (RP) is understudied.
Purpose Of The Study
- To investigate the impact of preoperative 5-ARI treatment on continence recovery and health-related quality of life (HRQOL) after RP.
- To assess long-term functional outcomes in PC patients treated with 5-ARI before RP.
Main Methods
- Propensity-score matched analysis of 442 PC patients undergoing RP (90 with preoperative 5-ARI, 352 without).
- Continence recovery assessed by pad usage and ICIQ-SF; HRQOL evaluated using EORTC QLQ-C30 and PR25.
- Multivariable Cox regression models analyzed the effect of 5-ARI on continence recovery.
Main Results
- Preoperative 5-ARI use was associated with significantly higher baseline ICIQ-SF scores.
- At 24 months post-RP, continence recovery was lower in the 5-ARI group (55.7% vs. 68.6%).
- 5-ARI was an independent predictor of impaired continence recovery (HR 0.50, p=0.03) and affected HRQOL up to 24 months.
Conclusions
- Preoperative 5-ARI treatment is associated with impaired long-term urinary continence recovery after radical prostatectomy.
- Findings suggest 5-ARI use prior to RP may negatively affect urinary function recovery.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....